Phase II study of XELOX as adjuvant chemotherapy for locally advanced rectal cancer

Phase II study of XELOX as adjuvant chemotherapy for locally advanced rectal cancer - CORONAII

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008429

Enrollment

Registered

2012-07-13

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced rectal cancer

Interventions

Adjuvant chemotherapy with XELOX for locally advanced rectal cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Writen informed consent (2)Histologically proven adenocarcinoma of the rectum (3)Clinical confirmed locally advanced rectal cancer (4)Without distant metastases (M0) (5)Age: 20-80 years (6)Performance status (PS) 0-1 (7)Alife expectancy greater than 12 weeks (8)Without prior radiotherapy for the pelvis (9)Adequate organ function

Exclusion criteria

Exclusion criteria: (1)Multiple malignacies to be treated (2)Uncontrollable peptic ulcer disease (3)Serious complications (4)Previous history of severe drug-induced allergy (5)Severe neuropathy (6)With interstitial lung disease or pulmonary fibrosis (7)Pregnant (8)Prior chemotherapy with oxaliplatin or capecitabin (9)Disqualified by attending doctor

Design outcomes

Primary

Measure	Time frame
3-y relapse-free survival rate	—

Secondary

Measure	Time frame
Local recurrence-free survival rate, Relative dose intensity, Safety	—

Countries

Japan

Contacts

Public ContactGoro Nakayama

Nagoya University Graduate School of Medicine Gastroenterological Surgery

goro@med.nagoya-u.ac.jp052-744-2253

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026